BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17513229)

  • 1. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Kiraç FS
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):214-5; author reply 218-9. PubMed ID: 17513229
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Cavuşoğlu Y
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):217-8; author reply 218-9. PubMed ID: 17513231
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Tandoğan I
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):216; author reply 218-9. PubMed ID: 17513230
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials.
    Cleland JG; Shelton R; Nikitin N; Ford S; Frison L; Grind M
    Eur J Heart Fail; 2007; 9(6-7):730-9. PubMed ID: 17360232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ximelagatran versus warfarin in the prevention of atrial fibrillation-related stroke: both sides of the story.
    Testa L; Van Gaal W; Agostoni P; Abbate A; Trotta G; Biondi-Zoccai GG
    Stroke; 2007 Jul; 38(7):e57. PubMed ID: 17510448
    [No Abstract]   [Full Text] [Related]  

  • 8. Ximelagatran or warfarin in atrial fibrillation?
    Epstein EF
    Lancet; 2004 Feb; 363(9410):736; author reply 736. PubMed ID: 15001338
    [No Abstract]   [Full Text] [Related]  

  • 9. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ; Lip GY
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ximelagatran or warfarin in atrial fibrillation?
    MacAllister R; Hingorani AD; Casas JP
    Lancet; 2004 Feb; 363(9410):735-6; author reply 736. PubMed ID: 15001337
    [No Abstract]   [Full Text] [Related]  

  • 11. Ximelagatran or warfarin in atrial fibrillation?
    Stöllberger C; Finsterer J
    Lancet; 2004 Feb; 363(9410):734-5; author reply 736. PubMed ID: 15001336
    [No Abstract]   [Full Text] [Related]  

  • 12. Ximelagatran or warfarin in atrial fibrillation?
    Eikelboom J; Hankey G
    Lancet; 2004 Feb; 363(9410):734; author reply 734, 736. PubMed ID: 15001334
    [No Abstract]   [Full Text] [Related]  

  • 13. Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics.
    Ezekowitz MD
    Am Heart Hosp J; 2004; 2(4 Suppl 1):31-5. PubMed ID: 15539973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trials and tribulations of non-inferiority: the ximelagatran experience.
    Kaul S; Diamond GA; Weintraub WS
    J Am Coll Cardiol; 2005 Dec; 46(11):1986-95. PubMed ID: 16325029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we pull the plug on warfarin in atrial fibrillation?
    Verheugt FW
    Lancet; 2003 Nov; 362(9397):1686-7. PubMed ID: 14643112
    [No Abstract]   [Full Text] [Related]  

  • 16. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
    Berry C; Norrie J; McMurray JJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):149-51. PubMed ID: 16025234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trials and tribulations of noninferiority: the ximelagatran experience.
    Albers GW; Diener HC; Frison L; Grind M; Horrow J; Nevinson M; Olsson SB; Partridge S; Petersen P; Vahanian A; Halperin JL;
    J Am Coll Cardiol; 2006 Sep; 48(5):1058; author reply 1059. PubMed ID: 16949503
    [No Abstract]   [Full Text] [Related]  

  • 18. Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties.
    Palagummi P; Saltzman H; Ezekowitz M
    Am Heart J; 2005 Jan; 149(1 Suppl):S32-5. PubMed ID: 15644791
    [No Abstract]   [Full Text] [Related]  

  • 19. [Ximelagatran: a promising new drug for oral anticoagulation].
    Scardi S; Giansante C
    Monaldi Arch Chest Dis; 2004 Mar; 62(1):34-9. PubMed ID: 15211735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation.
    Teitelbaum JS; von Kummer R; Gjesdal K; Kristinsson A; Gahn G; Albers GW;
    Can J Neurol Sci; 2008 May; 35(2):160-5. PubMed ID: 18574928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.